Tenax Therapeutics financials
$1.84−0.54%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — | $0.00 | — | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — | $0.00 | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$56.4M | -$19.5M | -$8.2M | -$11.1M | -$32.7M | -$9.8M | $8.6M | -$6.9M | $9.2M | -$52.7M |
| Net income | -$52.6M | -$17.6M | -$7.7M | -$11.0M | -$32.5M | -$9.9M | $8.4M | -$14.1M | $8.8M | -$43.9M |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-1.34 | $-1.15 | $-31.04 | $-600.71 | $-2524.80 | $-1520.00 | $2160.00 | $-14464.00 | $10032.00 | $-49984.00 |
| EBITDA | -$56.4M | -$19.5M | -$8.2M | -$11.0M | -$32.7M | -$9.7M | $8.7M | -$6.8M | $9.4M | -$18.7M |
| Operating cash flow | -$35.8M | -$14.8M | -$5.9M | -$11.4M | -$10.9M | -$9.3M | -$7.6M | -$5.5M | -$12.1M | -$15.9M |
| Free cash flow | -$35.8M | -$14.8M | -$5.9M | -$11.4M | -$10.9M | -$9.3M | -$7.6M | -$5.5M | -$12.1M | -$15.9M |
| Diluted shares | 39.2M | 15.3M | 0.2M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $97.6M | $94.9M | $9.8M | $2.1M | $5.6M | $6.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | $462.7K |
| Total debt | $0.00 | $0.00 | $501.0K | $624.3K | $0.00 | $244.7K |
| Total assets | $104.2M | $96.7M | $11.7M | $3.4M | $6.0M | $6.9M |
| Total liabilities | $7.2M | $4.7M | $3.6M | $1.9M | $1.7M | $2.2M |
| Shareholders' equity | $97.1M | $92.0M | $8.1M | $1.5M | $4.2M | $4.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology